Search Clinical Trials
Sponsor Condition of Interest |
---|
Life's End Benefits of Cannabidiol and Tetrahydrocannabinol
University of Southern California
Agitation
Dementia
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral
combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12
weeks. This study is designed to test the hypothesis that treatment with an oral combination... expand
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximately 150 participants of any gender at least 40 years of age who are hospice care-eligible with agitation and dementia (HAD). Participants will be randomized (50:50) to either active study drug (T2:C100) or placebo. The double-blind period of this study is 12 weeks. A 24 week optional open-label extension will be offered to participants who complete the double-period. Type: Interventional Start Date: Dec 2023 |
Pembro With Radiation With or Without Olaparib
Zin W Myint
Prostate Cancer
This trial will evaluate whether the immune-sensitizing effects of immunotherapy
(Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the
effects of immunotherapy in men with high-risk localized prostate cancer.
expand
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer. Type: Interventional Start Date: Jul 2023 |
Moringa Supplementation for Improved Milk Output
University of Kentucky
Breastfeeding
The overall objective is to obtain preliminary data on the effect of Moringa oleifera leaf
supplementation (moringa) at 4g daily for four weeks compared to placebo to improve human
milk quantity and quality and infant health. Hypothesis: Four grams of moringa daily by mouth... expand
The overall objective is to obtain preliminary data on the effect of Moringa oleifera leaf supplementation (moringa) at 4g daily for four weeks compared to placebo to improve human milk quantity and quality and infant health. Hypothesis: Four grams of moringa daily by mouth compared to placebo will increase breastmilk output and percent of mother's own milk consumed by infant. Type: Interventional Start Date: May 2022 |
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
Migraine
The main goal of the study is to assess the long-term safety of eptinezumab on children and
adolescents ages 6 to 17 with chronic or episodic migraine.
expand
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine. Type: Interventional Start Date: Dec 2021 |
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma
Primary CNS Lymphoma
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens (methotrexate/
temozolomide/rituximab... expand
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B) Type: Interventional Start Date: Dec 2021 |
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma...
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
Lymphoma
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity
of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after
lymphodepletion consisting of cyclophosphamide and fludarabine.
expand
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine. Type: Interventional Start Date: May 2021 |
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
Genmab
Malignant Solid Tumor
Non Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or
locally advanced solid tumors.
expand
To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors. Type: Interventional Start Date: Sep 2019 |
OASIS: Peer Support for T2DM in Appalachia (Peer Participant)
University of Kentucky
Diabetes Mellitus, Type 2
The goal of this clinical trial is to compare the effects of peer coaching models in older
adults with unmanaged type two diabetes. The main questions it aims to answer are:
Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management?
If effective,... expand
The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? If effective, which facets of the peer model are most effective? Peer coaches will Undergo peer coach training. Reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting. Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups. Type: Interventional Start Date: Feb 2024 |
The Syn-Sleep Study
CND Life Sciences
REM Sleep Behavior Disorder (iRBD)
In collaboration with approximately 8 centers that specialize in iRBD we will recruit a total
of 80 individuals for the study. All subjects will be enrolled into a 2-year longitudinal
study where skin biopsies will be performed at 3 sites on each patient at 12-month intervals... expand
In collaboration with approximately 8 centers that specialize in iRBD we will recruit a total of 80 individuals for the study. All subjects will be enrolled into a 2-year longitudinal study where skin biopsies will be performed at 3 sites on each patient at 12-month intervals (baseline, year 1, year 2). Plasma blood collection will be performed at 12-month intervals (baseline, year 1, year 2). Detailed quantified examination, cognitive evaluation, medical history, and questionnaires will be performed at each visit. Additional biomarker, imaging and clinical information (if available) will be obtained for the purpose of determining phenoconversion to clinically apparent synucleinopathy. Subjects enrolled in the study will have baseline evaluations and follow up visits at 12 and 24 months to define any changes to clinical diagnosis (clinical phenoconversion). Skin biopsies will be repeated at the 12- and 24-month follow up visits to determine the rate of P-SYN accumulation over time and the rates of nerve fiber degeneration within punch skin biopsies. Type: Observational Start Date: Sep 2022 |
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic...
National Cancer Institute (NCI)
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
Metastatic Prostate Neuroendocrine Carcinoma
Metastatic Prostate Small Cell Neuroendocrine Carcinoma
Stage IV Prostate Cancer AJCC v8
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with
prostate cancer with neuroendocrine differentiation that has spread to other places in the
body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both... expand
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both hormone-producing endocrine cells and nerve cells. These cells release hormones into the blood in response to a signal from the nervous system. Hormones are biological substances that circulate through the bloodstream to control the activity of other organs or cells in the body. Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Treatment with Lutetium Lu 177 dotatate may shrink the tumor in a way that can be measured in patients with metastatic prostate cancer with neuroendocrine differentiation. Type: Interventional Start Date: Dec 2023 |
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Fusion Pharmaceuticals Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Gastric Cancer
Ewing Sarcoma
This is a first-in-human Phase 1 clinical trial designed to investigate the safety,
tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058
in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.
expand
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours. Type: Interventional Start Date: Feb 2023 |
A University-Community Partnership to Reduce Exposure to Disinfection Byproducts In Appalachia
Anna Hoover
Disinfection By-products
Appalachian Kentuckians in Martin and Letcher Counties are grappling with a
health-threatening drinking water crisis arising from exposures to disinfection by-products
(DBPs). DBPs include trihalomethanes (THMs), haloacetic acids (HAAs), chlorate, and other
compounds that... expand
Appalachian Kentuckians in Martin and Letcher Counties are grappling with a health-threatening drinking water crisis arising from exposures to disinfection by-products (DBPs). DBPs include trihalomethanes (THMs), haloacetic acids (HAAs), chlorate, and other compounds that have been associated with a variety of adverse health effects, including increased risk of bladder cancer and cardiovascular birth defects. This study implements a multi-stakeholder, multi-method approach to improve understanding of, characterize spatial and temporal variations in, and reduce exposure to DBPs in these Appalachian Kentucky counties. Type: Interventional Start Date: Feb 2022 |
CHIlled Platelet Study "CHIPS"
Philip Spinella
Acute Blood Loss
A phase 3 randomized partial blind storage duration ranging study in patients undergoing
complex cardiac surgery that will compare the transfusion of cold stored platelets to
standard room temperature stored platelets. The primary objective is to establish that cold
stored... expand
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets. Type: Interventional Start Date: Oct 2021 |
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction...
Austin V Stone
ACL Injury
Meniscus Tear
Post-traumatic Osteoarthritis
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course
of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and
biochemical and imaging biomarkers of cartilage degradation. This study will specifically... expand
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery. Type: Interventional Start Date: Feb 2021 |
Pinhole Versus Tunnel for Soft Tissue Recession
Mohanad Al-Sabbagh
Gingival Recession
This is an assessor-blinded split-mouth randomized clinical study to compare root coverage
and gingival tissue thickness following two different surgical procedures for non-autologous
grafting: the pinhole surgical technique (PST) and tunnel technique.
expand
This is an assessor-blinded split-mouth randomized clinical study to compare root coverage and gingival tissue thickness following two different surgical procedures for non-autologous grafting: the pinhole surgical technique (PST) and tunnel technique. Type: Interventional Start Date: Jun 2020 |
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
Timothy Mullett
Cancer
Health Care Utilization
The C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare
Team and Healthcare System Level) that improves the coordination of care with
supportive/ancillary care providers and community services through the use of patient
navigation and a... expand
The C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services. Type: Interventional Start Date: Feb 2024 |
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc.
Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic
chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen
(BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in... expand
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory). Type: Interventional Start Date: Feb 2023 |
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Perspective Therapeutics
Neuroendocrine Tumors
Neuroendocrine Tumor of the Lung
Neuroendocrine Tumor of Pancreas
Neuroendocrine Carcinoma Metastatic
Neuroendocrine Tumor Carcinoid
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle
Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
expand
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Type: Interventional Start Date: Sep 2023 |
Cardiac Amyloid Biorepository
Andrew Kolodziej
Cardiac Amyloidosis
Use samples procured from patients to improve understanding of molecular, cellular, and
tissue-level processes produced by cardiac amyloidosis and therapeutic interventions.
expand
Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by cardiac amyloidosis and therapeutic interventions. Type: Observational Start Date: Dec 2021 |
Imatinib TDM in GIST
Reema A. Patel
Gastrointestinal Stromal Tumors
Imatinib can lead to long recurrence free survival in patients diagnosed with
gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality
of life for our patients. This study will use therapeutic drug monitoring to improve quality
of life... expand
Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. Free drug levels and pharmokinetics of imatinib will also be monitored. Type: Interventional Start Date: Mar 2024 |
CERAMENT™| Bone Void Filler Device Registry
BONESUPPORT AB
Orthopedic Disorder
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal
use.
expand
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal use. Type: Observational [Patient Registry] Start Date: Mar 2020 |
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
Roberto Gedaly
End Stage Renal Disease
This will be a single center, prospective, open-label, randomized, controlled trial comparing
Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end
stage renal disease listed for primary solitary kidney transplant. Transplant Surgery is not... expand
This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end stage renal disease listed for primary solitary kidney transplant. Transplant Surgery is not part of the study. Type: Interventional Start Date: Mar 2019 |
Pediatric Oncology Nutrition Intervention Trial
Corey Hawes
Pediatric Cancer
Nutrition Related Cancer
Nutrition Aspect of Cancer
Muscle Loss
Malnutrition, Child
Nearly 60% of pediatric patients diagnosed with cancer develop malnutrition caused by a
combination of disease burden, side effects of chemotherapy, and the intensity of cancer
treatment. These patients are known to have an increased risk of infection, treatment-related
toxicity,... expand
Nearly 60% of pediatric patients diagnosed with cancer develop malnutrition caused by a combination of disease burden, side effects of chemotherapy, and the intensity of cancer treatment. These patients are known to have an increased risk of infection, treatment-related toxicity, inferior clinical outcomes, and increased risk of mortality. Malnutrition may progress to cancer cachexia, characterized by anorexia, increased inflammation, decreased fat, and decreased muscle mass with subsequent weight loss, which is associated with decreased overall survival. The goal of the proposed research is to determine changes in body composition, weight status, and nutritional status between common nutrition interventions including oral nutrition supplements (ONS), appetite stimulants, and enteral nutrition (EN) among pediatric cancer patients. A secondary goal of this research is to utilize the findings to develop clinical nutrition guidelines for this patient population. The specific objective of the research proposed is to solve the lack of evidence to adequately treat nutritional deficits in the pediatric oncology population. Without this data, there is a lack of clinical consistency in the initiation and selection of appropriate nutrition interventions to provide a more definitive pathway of care. This study can help formulate a clinical guideline for this patient population before, during, and after treatment. Type: Interventional Start Date: Jan 2024 |
Fresh Carts for Mom's to Improve Food Security and Glucose Management
Alison Gustafson
Gestational Diabetes Mellitus in Pregnancy
Type 2 Diabetes Mellitus
This study will look at the benefit of decreasing food insecurity and improving glucose
control among women who either report gestational diabetes (GDM) at 20-28-weeks or have type
2 diabetes (T2DM) with a confirmed pregnancy. Participants will receive a grocery
prescription... expand
This study will look at the benefit of decreasing food insecurity and improving glucose control among women who either report gestational diabetes (GDM) at 20-28-weeks or have type 2 diabetes (T2DM) with a confirmed pregnancy. Participants will receive a grocery prescription with delivery through Instacart at the start of the study or after 12 weeks or frozen medically tailored meals delivered from Door Dash. Researchers will compare the grocery prescription program, MTM (medically tailored meals), relative to standard of care to see if the impact on these food as medicine programs can improve glucose control over 12-weeks as compared to standard of care. Type: Interventional Start Date: Sep 2023 |
Sponsor-Initiated OCS Heart Perfusion Registry
TransMedics
Heart Transplant
OHP-II Registry is a sponsor-initiated, multi-center, observational post-approval registry.
expand
OHP-II Registry is a sponsor-initiated, multi-center, observational post-approval registry. Type: Observational [Patient Registry] Start Date: Aug 2023 |
- Previous
- Next